{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["34(1)"],"submitter":["Hu B"],"pubmed_abstract":["Current treatments for prostate cancer (PC) inevitably lead to the development of resistance to androgen deprivation therapy, resulting in the emergence of castration-resistant prostate cancer (CRPC), which is currently considered incurable. In this study, we discovered that the loss of phosphatase and tensin homolog (PTEN) function, in combination with elevated poly(ADP-ribose) polymerase 1 (PARP1) expression, significantly shortens the survival of PC patients. Motivated by this finding, we developed an RNA-based therapeutic agent consisting of PARP1-targeting small interfering RNA (siRNA) (siPARP1) and PTEN-expressing mRNA (mPTEN), which were co-encapsulated in an ionizable lipid nanoparticle, named mPsiP@miLAND. Both siPARP1 and mPTEN were shown to individually attenuate tumor cell grow"],"journal":["Molecular therapy. Oncology"],"pagination":["201133"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12905993"],"repository":["biostudies-literature"],"pubmed_title":["Suppression of PARP1 enhances PTEN mRNA therapy in castration-resistant prostate cancer by glycolysis disruption."],"pmcid":["PMC12905993"],"pubmed_authors":["Yang H","Yang J","Fan Y","Zhang J","Wu P","Yang M","Liu Q","Hu B","Zhu C","Tang L","Huang Y","Zheng L","Kong S"],"additional_accession":[]},"is_claimable":false,"name":"Suppression of PARP1 enhances PTEN mRNA therapy in castration-resistant prostate cancer by glycolysis disruption.","description":"Current treatments for prostate cancer (PC) inevitably lead to the development of resistance to androgen deprivation therapy, resulting in the emergence of castration-resistant prostate cancer (CRPC), which is currently considered incurable. In this study, we discovered that the loss of phosphatase and tensin homolog (PTEN) function, in combination with elevated poly(ADP-ribose) polymerase 1 (PARP1) expression, significantly shortens the survival of PC patients. Motivated by this finding, we developed an RNA-based therapeutic agent consisting of PARP1-targeting small interfering RNA (siRNA) (siPARP1) and PTEN-expressing mRNA (mPTEN), which were co-encapsulated in an ionizable lipid nanoparticle, named mPsiP@miLAND. Both siPARP1 and mPTEN were shown to individually attenuate tumor cell grow","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Mar","modification":"2026-07-15T21:21:18.918Z","creation":"2026-07-09T10:15:18.191Z"},"accession":"S-EPMC12905993","cross_references":{"pubmed":["41696631"],"doi":["10.1016/j.omton.2026.201133"]}}